Trimetazidine
- Generic Name
- Trimetazidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O3
- CAS Number
- 5011-34-7
- Unique Ingredient Identifier
- N9A0A0R9S8
- Background
Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.
...
- Indication
Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
- Associated Conditions
- Angina Pectoris, Chronic Stable Angina Pectoris, Tinnitus, Vertigo, Decreased visual acuity caused by Vascular Disorders
- Associated Therapies
- -
"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06656442
- Locations
- 🇪🇬
Ain Shams University Hospital, Cairo, Egypt
Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Minia University
- Target Recruit Count
- 60
- Registration Number
- NCT06459193
- Locations
- 🇪🇬
Minia Oncology Center, Minya, Egypt
Benefits of Trimetazidine in MAFLD Pateints
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 60
- Registration Number
- NCT06140953
- Locations
- 🇪🇬
Maha Youssif Fekry, Giza, October 6, Egypt
The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Steen Hvitfeldt Poulsen
- Target Recruit Count
- 24
- Registration Number
- NCT05633563
- Locations
- 🇩🇰
Aarhus University Hospital, Department of Cardiology, Aarhus N, Danmark, Denmark
Efficacy of Trimetazidine in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT05556005
- Locations
- 🇪🇬
Ainshams university hospitals, Cairo, Egypt
The Effects of TMZ on Diabetic Nephropathy
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05147194
Effect of Trimetazidine on Radiotherapy-induced Heart Damage.
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04939857
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 21
- Registration Number
- NCT04788745
- Locations
- 🇬🇧
King's College London, London, United Kingdom
🇦🇺Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia
🇳🇱University Medical Centre Utrecht, Utrecht, Netherlands
Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Ministry of Health, Brazil
- Target Recruit Count
- 80
- Registration Number
- NCT04760821
- Locations
- 🇧🇷
Heart Institute (InCor-HCFMUSP), Sao Paulo, SP, Brazil
Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- National Research Center for Preventive Medicine
- Target Recruit Count
- 72
- Registration Number
- NCT04511520
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.